Table 1.

Patients’ characteristics

Patients’ characteristics	n = 15
Age, years	71.4 ± 6.8
Sex (female/male)	1/14
Smoking history, n (%)	14 (93.3)
Body Mass Index, mean ± SD	21.8 ± 3.0
Histopathology
Adenocarcinoma, n (%)	7 (46.7)
Squamous carcinoma, n (%)	6 (40.0)
NOS, n (%)	2 (13.3)
Performance status (2≤), n (%)	2 (13.3)
Driver mutations
EGFR mutation, n (%)	1 (6.7)
PD‐L1 expression
TPS ≤50%, n (%)	0 (0.0)
1% ≤ TPS < 50%, n (%)	5 (33.3)
TPS <1%, n (%)	5 (33.3)
Unknown, n (%)	5 (33.3)
Clinical Staging
stage 3A/B/C, n (%)	10 (66.7)
stage 4A/B, n (%)	4 (26.7)
Postoperative recurrence, n (%)	1 (6.7)
Initial anti‐PD‐L1 antibody
Atezolizumab, n (%)	14 (93.3)
Durvalumab, n (%)	1 (6.7)

EGFR, epidermal growth factor receptor; NOS, not otherwise specified; PD‐L1, programmed death‐ligand 1; TPS, tumor proportion score.